BioCardia Inc (BCDA)
NASDAQ:BCDA
Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$1.19
-$0.06(-2.59%)
At close: 4:00 PM EST
$1.19
-$0.06(-2.59%)
Day’s Range― - ―
52-Week Range$1.00 - $3.20
Previous CloseN/A
Volume12.78K
Average Volume (3M)1.15M
Market Cap
$13.02M
Enterprise Value$4.93M
Total Cash (Recent Filing)$2.50M
Total Debt (Recent Filing)$528.00K
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 13, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding10,940,372
10 Day Avg. Volume282,453
30 Day Avg. Volume1,147,607
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.55
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$15.50Price Target Upside1202.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAfter twelve cell and gene therapy clinical studies, including CardiAMP and CardiALLO trials, demonstrating a high safety standard, the company plans to submit the Helix biotherapeutic delivery system for approval to the FDA.
Patient OutcomesPatients experienced an average increase in exercise tolerance of 80 seconds and an average of 82% reduction in angina episodes vs. baseline.
Regulatory ApprovalPotential approval of proprietary biotherapeutic delivery device should strengthen financial position and support clinical progress.
Bears Say
Clinical Trial ResultsCardiAMP HF did not meet its primary composite endpoint.
BioCardia News
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $1.00 and its highest was $3.20 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is $13.02M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is May 13, 2026 which is in 27 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Mar 24, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.17.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.17.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 10,940,372 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -0.415%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioCardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
BCDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful clinical progress and several important near‑term regulatory and scientific catalysts—most notably statistically significant benefits in a predefined high‑risk subgroup, initiation of a confirmatory trial, and active regulatory engagements. However, there are material risks: primary endpoints in the full cohort narrowly missed statistical significance; cash on hand (~$2.5M) is limited relative to annual operating cash use (~$7.5M); enrollment is early and resource constrained; and regulatory pathway and potential post‑marketing commitments remain uncertain. Overall, positives around clinical data and multiple catalysts are tempered by financial runway and execution risks, making the tone balanced.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(1202.52% Upside)
Technical Analysis
AlphaTON Capital
―
―
BioRestorative Therapies
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
17.62% Insiders
0.92% Mutual Funds
1.74% Other Institutional Investors
78.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---